Protocols to assess the gastrointestinal side effects resulting from inhibition of cyclo-oxygenase isoforms

Area of Science:

• Pharmacology
• Gastroenterology
• Toxicology

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for their anti-inflammatory and analgesic properties.
• A significant clinical limitation of NSAIDs is their propensity to cause gastrointestinal (GI) side effects, including gastric erosions, ulcers, and enteropathy.
• These GI injuries involve the inhibition of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) isoforms.

Purpose of the Study:

• To outline in vivo methods for evaluating the potential of novel NSAIDs and selective COX inhibitors to induce gastric and small intestinal injury in rats.
• To describe methods for assessing the protective effects of novel agents against NSAID-induced gastrointestinal damage.

Main Methods:

• In vivo studies in rats to induce and assess acute gastric corpus lesions, chronic antral ulcers, and small intestinal enteropathy.
• Utilizing these models to evaluate the GI toxicity of novel NSAIDs and selective COX inhibitors.
• Employing the models to test the efficacy of potential gastroprotective agents.

Main Results:

• The described methods allow for the identification of agents that cause acute gastric and chronic antral damage, as well as small intestinal enteropathy.
• These methods can differentiate the mechanisms underlying gastric versus intestinal injury, despite both involving COX inhibition.
• The models are suitable for evaluating the gastroprotective potential of novel compounds against NSAID-induced GI injury.

Conclusions:

• Validated in vivo methods exist to assess the gastrointestinal safety profiles of NSAIDs and selective COX inhibitors in rats.
• These methodologies are crucial for the preclinical development of safer anti-inflammatory and analgesic agents.
• The findings support the use of these models in predicting and preventing NSAID-induced gastrointestinal toxicity.